EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitVergleichsstudieOpen Access · CC BY-NC-ND 4.0

Comparative Analysis of Bispecific Antibodies and CAR T‐Cell Therapy in Follicular Lymphoma

Fortunato Morabito, Enrica Antonia Martino, Maria Elena Nizzoli, Annalisa Talami, Stefano Pozzi, Massimo Martino, Antonino Neri, Massimo Gentile iD

European Journal of Haematology · 2025-01 · 114 (1) · 4-16

DOI: 10.1111/ejh.14335 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift European Journal of Haematology, online erschienen am 27.10.2024. Verfasst von Fortunato Morabito und 7 weiteren Autor:innen. Beteiligte Einrichtung: Gruppo Amici Dell'Ematologia Foundation-GrADE, Reggio Emilia, Italy. Hauptthemen laut MEDLINE: Lymphoma, Follicular, Antibodies, Bispecific, Immunotherapy, Adoptive. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 77 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The treatment landscape for relapsed/refractory follicular lymphoma (RR‐FL) is marked by a pivotal debate between chimeric antigen receptor T‐cell (CAR‐T) therapy and bispecific antibodies (BsAbs). While both CAR‐T therapy and BsAbs target similar immunobiology and molecular markers, their efficacy comparisons are hindered by the lack of direct clinical trial comparisons. Key trials, such as the ZUMA‐5 study, underscore axicabtagene ciloleucel (axi‐cel)'s efficacy in treating RR‐FL, achieving a 79% complete response rate with a median duration of response exceeding 3 years. Similarly, lisocabtagene maraleucel (liso‐cel) in the TRANSCEND FL study reports a 94% complete response rate, emphasizing robust outcomes in heavily pretreated patients. Among BsAbs, mosunetuzumab showed promise in the GO29781 trial, with a 62% overall response rate in heavily pretreated RR‐FL patients. Thus, CAR‐T therapy offers potential curative benefits with a single infusion. However, its efficacy is tempered by significant adverse events such as cytokine release syndrome (CRS), neurotoxicity, and cytopenias, requiring specialized management and patient monitoring. In contrast, BsAbs provide a more tolerable treatment option counterbalancing by lower response rates and frequent dosing requirements. Personalized treatment strategies are crucial because of these distinct efficacy and safety profiles. When considering cost‐effectiveness, both therapies need to be evaluated in the context of their clinical outcomes and quality of life improvements. Cost‐effectiveness considerations are essential; while CAR‐T therapies incur higher initial costs, their potential for long‐term remission may mitigate expenses associated with repeated treatments or hospitalizations. Future research into resistance mechanisms and optimal therapeutic sequencing will further refine RR‐FL management strategies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lymphoma, FollicularAntibodies, BispecificImmunotherapy, AdoptiveHumansTreatment OutcomeClinical Trials as TopicCombined Modality TherapyReceptors, Chimeric AntigenAntineoplastic Agents, ImmunologicalDisease Management

Stichwörter der Autor:innen

BsAbsCAR‐Tcost‐effectivenessfollicular lymphoma

Substanzen

Antibodies, BispecificReceptors, Chimeric AntigenAntineoplastic Agents, Immunological

Autor:innen und Institutionen

  • Gruppo Amici Dell'Ematologia Foundation-GrADE, Reggio Emilia, Italy.
  • Hematology Unit, Department of Onco-Hematology, AO of Cosenza, Cosenza, Italy.
  • Hematology Unit, Azienda USL-IRCSS di Reggio Emilia, Reggio Emilia, Italy.
  • Department of Hemato-Oncology and Radiotherapy, Hematology and Stem Cell Transplantation and Cellular Therapies Unit (CTMO), Grande Ospedale Metropolitano "Bianchi-Melacrino-Morelli", Reggio Calabria, Italy.
  • Scientific Directorate, Azienda USL-IRCCS di Reggio Emilia, Reggio Emilia, Italy.
  • Department of Pharmacy, Health and Nutritional Science, University of Calabria, Rende, Italy.

ORCID-Profile: Massimo Gentile

Zitieren

APA

Morabito, F., Martino, E. A., Nizzoli, M. E., Talami, A., Pozzi, S., Martino, M., Neri, A., & Gentile, M. (2025). Comparative Analysis of Bispecific Antibodies and CAR T‐Cell Therapy in Follicular Lymphoma. European Journal of Haematology, 114(1), 4-16. https://doi.org/10.1111/ejh.14335

Vancouver

Morabito F, Martino EA, Nizzoli ME, Talami A, Pozzi S, Martino M, et al. Comparative Analysis of Bispecific Antibodies and CAR T‐Cell Therapy in Follicular Lymphoma. European Journal of Haematology. 2025;114(1):4-16. doi:10.1111/ejh.14335

BibTeX
@article{Morabito2025,
  author = {Morabito, Fortunato and Martino, Enrica Antonia and Nizzoli, Maria Elena and Talami, Annalisa and Pozzi, Stefano and Martino, Massimo and Neri, Antonino and Gentile, Massimo},
  title = {Comparative Analysis of Bispecific Antibodies and CAR T‐Cell Therapy in Follicular Lymphoma},
  journal = {European Journal of Haematology},
  year = {2025},
  volume = {114},
  number = {1},
  pages = {4--16},
  doi = {10.1111/ejh.14335}
}
Kostenlos starten →